insights_auto
Why is TRVN down 99,24%?
Dive Deeperchevron_right
TRVN:OTCMKTS
Trevena Inc
0,00050 USD
arrow_downward
-99,24%(-0,066) 1D
16-окт., 11:36:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TRVN...
Open
0,00 USD
High
0,00 USD
Low
0,00 USD
Mkt. cap
407,21
Avg. vol.
210,00
Volume
4,12 миң
52-wk high
1,50 USD
52-wk low
0,00 USD
Beta
1,07
Shares outstanding
864,00 миң
No. of employees
23
Open
0,00 USD
High
0,00 USD
Low
0,00 USD
Mkt. cap
407,21
Avg. vol.
210,00
Volume
4,12 миң
52-wk high
1,50 USD
52-wk low
0,00 USD
Beta
1,07
Shares outstanding
864,00 миң
No. of employees
23
News stories
From web sources and news partners
Seeking Alpha
·
29 мүнөт мурун
Nasdaq plunges 2% and these 15 names have led the downward decline
The Motley Fool
·
1 саат мурун
The Stock Market Has Seen This Happen Only 2 Other Times in Over 150 Years, and History Has an Ominous Warning for Investors
Simply Wall Street
·
1 саат мурун
Walmart (WMT) Adds Premium Wellness Products To More Than 2,300 Stores
CNBC
·
2 саат мурун
Anything not tied to artificial intelligence took off this week
Profile
Trevena, Inc. is a clinical stage biopharmaceutical company, headquartered in Chesterbrook, Pennsylvania, USA, and is involved in the discovery and development of G-protein coupled receptors biased ligands. Trevena was founded in 2007 with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry and Howard Rockman. Trevena's approach to drug discovery is based on utilizing ligand bias, or functional selectivity, at GPCR targets to produce drugs with improved efficacy and reduced side effect profiles. Trevena was named one of the top 15 US startups of 2008 by Business Week.
Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson's disease. Wikipedia
About Trevena Inc
CEO-
Employees23
Founded2007
HeadquartersАтланта, Джорджия, Америка Кошмо Штаттары
Sector-
Websitetrevena.com